SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

BioNTech SE - ADR

Mixed oncology-trial results are driving attention: traders cite BioNTechs BNT113 setback and modest breast-cancer benefit, while bulls point to other promising pipeline readouts and upcoming updates. Debate also reflects concern over the leadership transition and the time needed to turn the pipeline into commercial products.

Twilio, Inc. engages in the development of communications software, cloud-based platforms, and services. It operates through Twilio Communications and Twilio Segments. The Twilio Communications segment includes the platforms Messaging and Voice. The Twilio Segment involves Segment, Engage, Flex, Email, and others. The company was founded by John Wolthuis, Jeffery G. Lawson, and Evan Cooke in March 2008 and is headquartered in San Francisco, CA.

Twilio Inc - Ordinary Shares Class A

Twilio Inc

Twilios quarterly results beat expectations and lifted its full-year outlook, but a softer next-quarter organic growth forecast signaled deceleration and drove a sharp selloff. Traders are debating whether slowing messaging growth and weaker customer expansion outweigh the strong results, while some see the pullback as a potential bounce opportunity.

Schwab Strategic Trust - Schwab US Dividend Equity ETF

Schwab US Dividend Equity ETF

SCHD is drawing attention as traders discuss a shift from volatile technology and growth stocks toward dividend-paying value and defensive holdings amid market uncertainty. Many point to its recent strength and keep accumulating, while others question its yield and warn that rising Treasury yields or a return to tech could weigh on the fund.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Traders are focused on whether Q3 results will show that oral Wegovy demand and international expansion can offset concerns about Eli Lillys competitive lead in GLP-1 drugs. The community is divided: some see the pill rollout and low valuation as recovery potential, while others remain cautious about Novos execution, management and pipeline; the Hengrui licensing deal also drew debate as a longer-term pipeline move.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

A sharp breakout to a fresh 52-week high has put TGTX in focus, with traders pointing to BRIUMVIs commercial growth and anticipation of earnings and upcoming subcutaneous data. Buyout and short-squeeze theories are circulating, but remain speculation; others see the rally as momentum ahead of those catalysts.

Carvana Co. is a holding company and an eCommerce platform, which engages in the buying and selling of used cars. The company was founded by Ernest Garcia, III, Benjamin Huston and Ryan Keeton in 2012 and is headquartered in Tempe, AZ.

Carvana Co. - Ordinary Shares - Class A

Carvana Co.

Carvanas Q3 report, with record sales and revenue growth but an EPS miss and weaker margins, sparked a sharp rally and renewed short-squeeze speculation; traders are also citing the SECs decision to close its investigation without recommending enforcement. The move has drawn competing views, with bulls focused on growth and squeeze potential while bears question profitability, guidance and valuation.

Almonty Industries, Inc. engages in the mining, processing, and shipment of tungsten concentrates. Its projects include Almonty Korea Tungsten, Panasquiera mine, Gentung, Almonty Korea Moly, Los Santos mine, and Valtreixal. The company was founded on September 28, 2009 and is headquartered in Dillon, MT.

Almonty Industries Inc

A sharp selloff and persistent volatility dominate discussion, with traders pointing to broader weakness in miners and uncertainty over Sangdongs production ramp and near-term cash flows. Some remain bullish on tungsten-market fundamentals and the mines first shipment, while others say the investor-day discussion offered little new detail and are concerned about execution.

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Regeneron Pharmaceuticals, Inc.

Regenerons strong third-quarter earnings, supported by growth in Dupixent and Eylea HD, sparked a sharp share-price surge and a new 52-week high. Traders are broadly bullish on the breakout, while debating whether the move can hold or will retrace.

Crown Castle, Inc. engages in the business of owning, operating, and leasing shared communications infrastructure. It operates through the following segments: Towers, Fiber, and Other. The Towers segment focuses on providing coverage and capacity for wireless carrier network deployments. The Fiber segment includes communications infrastructure offerings of small cells and fiber solutions. The Other segment is involved in corporate assets such as cash and cash equivalents. The company was founded by Ted B. Miller Jr. and Edward C. Hutcheson Jr. in 1994 and is headquartered in Houston, TX.

Crown Castle Inc

Crown Castle International Corp

Reports that SpaceX is in talks to access at least 80,000 U.S. cell sites, including Crown Castles towers, have focused attention on the prospect of a major new leasing customer. Traders see potential tower revenue upside, while skeptics note that no agreement is signed and question whether SpaceXs wireless plans will translate into meaningful demand.

Aehr Test Systems engages in the design, manufacture, market, and sale of test and burn-in equipment used in the semiconductor industry. Its products include FOX-XP, FOX-NP, and FOX-CP wafer contact parallel test and burn-in systems, the WaferPak full wafer contactor, the DiePak Carrier, the WaferPak Aligner, the DiePak Autoloader, and test fixtures. The company was founded by Rhea J. Posedel on May 25, 1977 and is headquartered in Fremont, CA.

Aehr Test Systems

A steep selloff in Aehr shares is driving discussion as traders debate whether broader AI and semiconductor weakness, valuation concerns and bearish options flow point to more downside or an oversold setup ahead of earnings. Bulls are watching guidance, backlog and potential AI test-system orders, while skeptics question execution and the companys ability to justify its valuation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Teradyne shares are under pressure despite a strong Q3 earnings beat, as traders focus on a flat-to-cautious Q4 outlook, lower margins and valuation concerns. Some see the AI-driven growth and earnings strength as reasons to buy the dip, while others worry the guidance does not justify the stocks valuation.

FORM Drops 12% Post Q3 Earnings: Should You Buy the Stock on the Dip?

FormFactor shares plunge nearly 12% after Q3 earnings as weak Q4 guidance and capacity constraints weigh on sentiment. Can AI demand and expansion fuel a rebound?

FORM's HBM and Foundry Testing Gain From AI Demand: What's Ahead?

FormFactor's HBM4 testing and growing foundry business are benefiting from AI chip complexity.

Teradyne Q3 Earnings Call Highlights AI Demand and 2027 Growth Plans

TER's AI-driven growth outlook for 2027 is fueled by expanding compute programs, record memory test revenue and capacity investments amid margin pressures.

Teradyne Q3 Earnings Beat Estimates, Revenues Increase Year over Year

TER's Q3 2026 earnings surge 169.4% as AI-driven demand fuels record revenues in Memory and Integrated Systems Test, boosting sales and profitability.


Teradyne Q3 26 Earnings Conference Call At 8:30 AM ET

(RTTNews) - Teradyne Inc. (TER) will host a conference call at 8:30 AM ET on October 28, 2026, to discuss Q3 26 earnings results...

Zacks Investment Ideas feature highlights: Teradyne, Lam Research and ATI

Teradyne, Lam Research and ATI offer exposure to AI infrastructure, semiconductor equipment and aerospace growth, with projected earnings gains and PEG ratios below 1.0.

Teradyne (TER) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

While the top- and bottom-line numbers for Teradyne (TER) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Teradyne (TER) Tops Q3 Earnings and Revenue Estimates

Teradyne (TER) delivered earnings and revenue surprises of +12.26% and +2.77%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Teradyne Reports Third Quarter 2026 Results

Teradyne, Inc. (NASDAQ: TER): Q3'26 Q3'25 Q2'26 Revenue (mil) $ 1,306 $ 769 $ 1,329 GAAP EPS $ 2.17 $ 0.75 $ 2.38 Non-GAAP EPS $ 2.29 $ 0.85 $ 2.47 Teradyne, Inc. (NASDAQ: TER) reported revenue of $1,306 million for the third quarter of 2026 of which $1,072 million was in Semiconductor Test, $138...

Equities Bounce: 3 Top Ranked Stocks to Buy Now (TER, LRCX, ATI)

Shares of Teradyne, ATI INC and Lam Research stand out for their long term growth forecasts, and now compelling valuations following the recent selloff.

Teradyne's Q4 2026 guidance is revenue of $1.25B to $1.35B, GAAP net income per diluted share of $1.88 to $2.18, and non-GAAP net income per diluted share of $1.95 to $2.25.

Teradyne's Q3'26 revenue and GAAP EPS were below Q2'26; operating income and gross margin were below Q2'26; disclosed risks include decreased or delayed product demand from significant customers and export controls.

Teradyne reported revenue up 70% and earnings up over 150% from Q3'25, record revenue in Memory and Integrated Systems Test driven by all things AI, and Robotics' highest third-quarter revenue and profitability.

Teradyne, Inc. engages in the development and sale of automatic test systems. It operates through the following business segments: Semiconductor Test, Robotics, and All Other. The Semiconductor Test segment designs, manufactures, and markets semiconductor test products and services. The Robotics segment includes operations related to the design, manufacturing, and marketing of collaborative robotic arms, autonomous mobile robots, and advanced robotic control software. The company was founded by Alexander V. d'Arbeloff and Nicholas DeWolf in 1960 and is headquartered in North Reading, MA.

Teradyne, Inc.

Teradyne Partners With GS Microelectronics On New Semiconductor Test Center — Targets AI, Silicon Photonics And Auto Chips

Equity

Bullish Sentiment

<ul class="summary-bullets"><li>The new 42,000-square-foot Silicon Valley facility will serve AI, silicon photonics, automotive, RF and power-management chips.</li><li>The companies will jointly pursue customers to accelerate Teradyne-based design wins and broader adoption.</li><li>GSME is expanding its test-engineering team across the U.S., Taiwan, Europe and the Gulf Cooperation Council region</li></ul>Teradyne Inc. (TER) shares rose Tuesday after the semiconductor-testing company announced a multi-year partnership with GS Microelectronics U.S. to establish a new test-and-evaluation center focused on AI and other next-generation chips.The center will combine GSME’s chip design and manufacturing capabilities with Teradyne’s automated test systems, helping customers move more quickly from device evaluation and engineering development to production.<h2 class="st-heading-2">New Center Targets AI And Silicon Photonics Chips</h2>GSME will operate a dedicated Teradyne-equipped test floor at its new 42,000-square-foot Silicon Valley headquarters. The facility will support chip developers working across AI, silicon photonics, automotive, power management, and radio-frequency technologies.Customers can use the center for demonstrations, device evaluations, engineering development, pilot production, and technical training, with access to Teradyne's test handlers and probers. The facility is scheduled to open in the fourth quarter of 2026.The partnership also has a commercial component. GSME and Teradyne plan to work together on joint sales engagements, target accounts, technical workshops and customer briefings, with the stated goal of accelerating Teradyne-based design wins and expanding market adoption.GSME is also expanding its test-engineering team across the U.S., Taiwan, Europe and the Gulf Cooperation Council region to support customer programs and application-specific requirements.<h2 class="st-heading-2">AI Complexity Is Increasing The Need For Chip Testing</h2>As semiconductor designs grow more complex, driven by AI data center buildouts, rapid access to high-performance test development capabilities becomes essential, Teradyne Semiconductor Test Group President Shannon Poulin said.He added that combining Teradyne’s test platforms with GSME’s engineering capabilities is intended to help customers move more efficiently “from development into volume production.”That demand is already showing up in Teradyne’s business. Its Semiconductor Test segment generated a record $1.12 billion in revenue in the fiscal second quarter (Q2), up 128.1% year over year, primarily due to higher AI-related compute and memory sales.Overall Q2 revenue reached $1.33 billion, up 104% from $652 million a year earlier. The company’s semiconductor-testing business hit a record for the second consecutive quarter, driven by continued AI investment across the compute and memory markets.The company also recorded more than $200 million in memory-test revenue for a third straight quarter, supported by demand for high-bandwidth memory (HBM) and DRAM testing for AI compute deployments.<h2 class="st-heading-2">Retail Sentiment Around TER Stock</h2>Retail investor sentiment around&nbsp;<a href="https://stocktwits.com/symbol/TER">TER</a> stock remained ‘neutral’ on Stocktwits.<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_09_22_221457_19d6bc78a8.png" alt="Screenshot 2026-09-22 221457.png" width="812" height="437"><figcaption>TER stock retail sentiment on September 22 as of 01:00 p.m. ET | Source: Stocktwits</figcaption></figure>So far this year, Teradyne shares have surged nearly 90%. In comparison, the ARK Autonomous Technology &amp; Robotics ETF (<a href="https://stocktwits.com/symbol/ARKQ">ARKQ</a>), which holds the stock, has risen around 5% over the same period.See Also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/paypal-joins-meta-s-muse-checkout-ecosystem-partnership-extends-ai-shopping-across-its-merchant-network/cZMPtqaRBe6">PayPal Joins Meta’s Muse Checkout Ecosystem — Partnership Extends AI Shopping Across Its Merchant Network</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration, the Teradyne logo is seen displayed on a smartphone screen.

Teradyne Inc. (TER) shares rose Tuesday after the semiconductor-testing company announced a multi-year partnership with GS Microelectronics U.S. to establish a new test-and-evaluation center focused on AI and other next-generation chips.

The multi-year partnership gives chip developers access to Teradyne’s advanced test systems as increasingly complex AI and next-generation semiconductor designs require more intensive evaluation before production.

ARK Autonomous Technology & Robotics ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$274.37
Prev Close	$296.23
Open	$277.54
Dividend Yield	0.25%
50-Day Moving Average	$364.21
Beta	2.33
Avg. Volume	2.47M
PE Ratio	31.51

52-Week High	$487.91
52-Week Low	$151.52
Market Capitalization	$42.9B
EPS (Annual)	$3.47
Price to Book	12.48
Revenue Per Employee	$483,215.91

Feed

News

Sentiment

Earnings

Fundamentals

Info

TER Fundamentals